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Rationale: Chronic obstructive pulmonary disease (COPD) is a phenotypically heterogeneous disease. In COPD, the
presence of emphysema is associated with increased mortality and risk of lung cancer. High resolution computed
tomography (HRCT) scans are useful in quantifying emphysema but are associated with radiation exposure and
high incidence of false positive findings (i.e., nodules). Using a comprehensive biomarker panel, we sought to
determine if there was a peripheral blood biomarker signature of emphysema.
Methods: 114 plasma biomarkers were measured using a custom assay in 588 individuals enrolled in the
COPDGene study. Quantitative emphysema measurements included percent low lung attenuation (%LAA)≤ −950
HU, ≤ − 910 HU and mean lung attenuation at the 15th percentile on lung attenuation curve (LP15A). Multiple
regression analysis was performed to determine plasma biomarkers associated with emphysema independent of
covariates age, gender, smoking status, body mass index and FEV1. The findings were subsequently validated using
baseline blood samples from a separate cohort of 388 subjects enrolled in the Treatment of Emphysema with a
Selective Retinoid Agonist (TESRA) study.
Results: Regression analysis identified multiple biomarkers associated with CT-assessed emphysema in COPDGene,
including advanced glycosylation end-products receptor (AGER or RAGE, p < 0.001), intercellular adhesion molecule 1
(ICAM, p < 0.001), and chemokine ligand 20 (CCL20, p < 0.001). Validation in the TESRA cohort revealed significant
associations with RAGE, ICAM1, and CCL20 with radiologic emphysema (p < 0.001 after meta-analysis). Other biomarkers
that were associated with emphysema include CDH1, CDH 13 and SERPINA7, but were not available for validation in
the TESRA study. Receiver operating characteristics analysis demonstrated a benefit of adding a biomarker panel to
clinical covariates for detecting emphysema, especially in those without severe airflow limitation (AUC 0.85).
Conclusions: Our findings, suggest that a panel of blood biomarkers including sRAGE, ICAM1 and CCL20 may serve as
a useful surrogate measure of emphysema, and when combined with clinical covariates, may be useful clinically in
predicting the presence of emphysema compared to just using covariates alone, especially in those with less severe
COPD. Ultimately biomarkers may shed light on disease pathogenesis, providing targets for new treatments.
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Chronic obstructive pulmonary disease (COPD) is a
phenotypically heterogeneous condition characterized by
airflow limitation that is not fully reversible [1]. Some, but
not all, COPD subjects have emphysema, i.e., airspace en-
largement distal to the terminal bronchioles [2]. Deter-
mining the presence of emphysema is important, as it has
been independently associated with increased respiratory
symptoms, more rapid decline in lung function, increased
risk of lung cancer, higher rates of cardiovascular disease
and increased mortality risk [3-6]. Surprisingly, there are
some subjects with significant smoking history that have
emphysema, but no airflow limitation [7]. Understanding
the molecular signatures underlying emphysema may shed
light on the pathogenesis of emphysema and its systemic
complications.
The best current non-invasive method of detecting em-
physema is high-resolution computed tomography
(HRCT) [8,9]. The drawbacks to HRCT include cost, radi-
ation exposure, and a high rate of false positive clinical sig-
nificant findings (e.g. benign nodules); however, HRCT can
provide significant information relevant to lung pathology.
For instance, lung attenuation area (LAA) at −950 or −910
Hounsfield units (HU) and the mean lung attenuation
value at the 15th percentile (LP15A) on the lung attenu-
ation curve are density-based measurements that correlate
with emphysema [8,10,11]. Although the optimal method
and normal values for describing radiologic emphysema
have not been fully validated, it has been shown that con-
trol smokers without COPD have percent LAA ≤ −950
HU of <5% [9].
The first reported blood biomarker of emphysema was
α1-antitrypsin (AAT); however, AAT deficiency accounts
for only 1-2% of COPD [12]. Another recently reported in-
dependent biomarker of emphysema is soluble RAGE or
advanced glycosylation end product receptor (AGER) [13].
Peripheral blood adiponectin and bronchoalveolar lavage
fluid eotaxin levels have also correlated with radiologic
emphysema [14,15]. There are other reports of peripheral
blood biomarkers of airflow limitation such as interleukin-
6, surfactant protein D and C-reactive protein [16,17].
Therefore, the presence of systemic biomarkers in periph-
eral blood, which can be easily measured and offer infor-
mation regarding COPD phenotypes, may provide another
method of significant value in diagnosing and managing
individuals with emphysema [18]. In addition, a biomarker
signature of emphysematous phenotypes may provide
insight to the pathogenesis of disease. Limitations of some
previous emphysema biomarker studies include small
sample size and lack of replication. With this in mind,
using one of the largest studies to date, we sought to de-
termine a peripheral blood biomarker signature of emphy-
sema, independent of other clinical variables, in current
and former cigarette smokers with normal lung functionand with COPD, and relate the biomarker signature to dif-
ferent methods of defining radiologic emphysema. Key
findings were validated in an independent COPD cohort.
Methods
Study population
COPDGene is a multi-centered study of the genetic epi-
demiology of COPD that enrolled 10,192 non-Hispanic
White and African-American individuals, aged 45–80
years old with at least a 10 pack-year history of smoking,
who had not had an exacerbation of COPD for at least
the previous 30 days. Additional information on the
COPDGene study and the collection of clinical data has
been described previously [19]. 1839 COPDGene sub-
jects (1599 non-Hispanic White (NHW) and 240 non-
Hispanic Black) had fresh frozen plasma collected using a
p100 tube (BD) at five COPDGene sites (National Jewish
Health (N =916), University of Iowa (N =670), Harbor-
UCLA Medical Center (N =202), Temple University
(N =36), and Baylor Medical Center (N =15)). From this
cohort a subset of 602 NHW subjects (no non-Hispanic
Black subjects included due to limited numbers) were se-
lected for a comprehensive biomarker study with an at-
tempt to obtain a range of GOLD stages and match groups
as closely as possible based on age, gender and smoking
history. Of the 602 subjects, 588 subjects had quantitative
HRCT measurements available. The institutional review
boards of participating institutions approved the study
(Additional file 1: Table S1).
A separate validation cohort of 388 individuals (all former
smokers with COPD) was obtained from the Treatment of
Emphysema with a Selective Retinoid Agonist (TESRA)
study. TESRA was a multi-centered randomized controlled
trial assessing the safety and efficacy of palovarotene in ex-
smokers with COPD. Only baseline samples before treat-
ment were used for biomarker determination. Emphysema
was quantitatively assessed by low dose spiral CT in the
TESRA cohort. Additional information on the TESRA
study has been described previously [20].
Clinical data and definitions
COPD was defined as post bronchodilator ratio of forced
expiratory volume in the first second (FEV1) to forced vital
capacity (FVC) <0.70. Current or ex-smokers without spi-
rometric evidence of airflow obstruction (FEV1/FVC ≥0.70)
were classified as controls [1].
COPDGene study patients underwent whole lung volu-
metric multi-detector computed tomography (CT) as pre-
viously described [19,21]. Quantitative analysis of lung
density was performed using the Slicer software package
(http://www.slicer.org). Emphysema was primarily quanti-
fied by the percent of lung voxels (%LAA) ≤ −950 HU on
the inspiratory images of CT scans for the whole lung.
Emphysema was additionally quantified by percent of lung
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and as mean lung attenuation at the 15th percentile
on lung volume-adjusted attenuation curve (LP15A).
In the TESRA cohort emphysema was quantified as
%LAA ≤ −910 HU and LP15A on HRCT scans [20].
Densiometric analyses of the HRCTs were completed in
a central lab (BioClinica, Leiden, The Netherlands)
using PulmoCMS software (Medis specials, Leiden, The
Netherlands). The study design and clinical outcomes
have been previously reported [13,20].
Biomarker selection and measurement
For the COPDGene cohort, 114 candidate biomarkers
were selected based on a review of the literature and pre-
viously reported pilot work from the BIOSPIR group [22].
Biomarker levels were determined using a custom 15-panel
assay created by Myriad-RBM (Austin, TX) multiplex tech-
nology. Blood samples were drawn from non-fasting indi-
viduals. Approximately 8.5 mL of blood was withdrawn
from the ante-cubital vein into a sterile 13 × 1000 mm
P100 Blood Collection Tube (BD, New Jersey, USA). The
sample was immediately centrifuged at 2500 × g, 20 minutes
at room temperature. Aliquots in 500 μL tubes were
stored at −80°C until analyzed. In the TESRA cohort, 111
similarly chosen protein biomarkers were measured in
ethylenediamine-tetraacetic acid (EDTA) plasma in dupli-
cate at Rules Based Medicine (Austin, TX) and Quest
Diagnostics (Valencia, CA). A full list of biomarkers ana-
lyzed in the TESRA study has been published [13]
Statistical analysis
Differences in demographic characteristics of study
subjects were analyzed using a t-test for continuous
variables and a Chi-squared test for categorical vari-
ables. Emphysema severity was classified as none, mild,
moderate and severe. For %LAA ≤ −950 HU the cutoffs
were <5%, 5- < 10%, 10- < 20% and ≥20%, respectively,
while for %LAA ≤ −910 HU the cutoffs were <35%, 35- <
45%, 45- < 55% and ≥55%, respectively. Cutoffs were based
on mean values from COPDGene studies and balancing
the sample size in each group [9].
Biomarkers (n = 17) with >10% and <95% of values
below the lower limit of quantitation (LLOQ) for that par-
ticular biomarker were transformed into binary variables
(present or absent). Biomarkers (n = 16) with >95% values
below LLOQ were excluded from the analysis. For regres-
sion analysis, the remaining biomarker levels (n = 81)
underwent an empirical normal quantile transformation
projecting the ranks onto an inverse normal distribution
so that they resemble a normal distribution and allow com-
parison of biomarkers at different concentrations. Non-
transformed biomarker levels are also presented (Additional
file 1: Table S3). Collinearity among biomarkers and covari-
ates was assessed using Pearson correlation. Collinearity(R > 0.6) was observed between proinsulin intact (INS in-
tact) and proinsulin total (INS total) so INS intact was
removed from the analysis. Also, brain derived neuro-
tropic factor (BDNF) was removed, as it was collinear with
angiopoietin 1, CCL5 (T cell specific protein RANTES),
epithelial-derived neutrophil-activating protein 78, alpha-1
antitrypsin and latency associated peptide of transforming
growth factor beta 1. For modeling of multiple biomarkers,
stepwise regression, with a combination of backwards
and forwards selection and a p-value threshold <0.15
for entry and exit from the model, was used to arrive at
the final model. A p-value of <0.05 was taken as statisti-
cally significant for association with the outcome em-
physema variables.
To perform the meta-analysis, a single variable model
was fit for each of the significant biomarkers that were also
identified in the TESRA study. Equivalent covariates were
included for the two studies and an ordered logistic and lin-
ear regression was fit respectively for the %LAA ≤ −910 HU
and LP15A outcomes. P-values from both studies were
combined by calculating the average Z-score of the inverse
normal quantiles of the two p-values to determine a com-
bined p-value that accounted for consistent effects of the
biomarker levels on emphysema severity in the two studies
[23]. A Bonferroni adjustment was applied based on all
tested markers.
Receiver operating characteristic (ROC) curves were
generated for covariates alone and covariates with bio-
markers with the presence of emphysema compared to
no emphysema as the outcome. Nominal logistic regres-
sion was performed, with emphysema considered
present if %LAA ≤ −950 HU was ≥5% compared to no em-
physema (%LAA ≤ −950 HU <5%). Similarly, ROC curves
were generated including different severities of airflow limi-
tation based on FEV1 percent predicted. Statistical analyses
were performed using JMP 9.0 (SAS Institute, Cary, NC)
and R (version 3.0.2) statistical software packages [24].
Results
Study population
Demographics, physiology, quantitative HRCT measure-
ments and patient-reported outcomes for COPDGene
and TESRA cohorts are listed in Table 1. In the COPD-
Gene biomarker study, there were 588 individuals with
complete data available. Subjects with COPD were sig-
nificantly older, had lower BMI, higher pack-year history
of smoking and worse SGRQ scores compared to those
without COPD (p < 0.01, all comparisons). The distribu-
tion of gender and current smokers was similar between
non-COPD and COPD groups. The following variables
were associated with emphysema (LAA ≤ −950 HU): lower
FEV1 (p < 0.001), lower body mass index (p < 0.001), male
gender (p = 0.002), older age at enrollment (p = 0.038) and
current non-smoking status (p < 0.001); these variables
Table 1 Demographics of individuals in COPDGene and TESRA studies*
COPDGene (n = 588) TESRA
No COPD
n = 247
COPD
n = 341
p-value COPD
(n = 388)
Demographics
Age (years) 61 ± 3 65 ± 0.5 p < 0.01 66.6 ± 0.4
Gender (male/female) 124/123 178/163 p = 0.63 267/121
Current smokers (%) 27 23 p = 0.23 0
Smoking history (pack-years) 38 ± 1 54 ± 2 p < 0.001 48 ± 1
Body mass index (kg/m2) 28.9 ± 2.3 27.8 ± 0.3 p = 0.009 26 ± 0.2
Physiology
FEV1 post bronchodilator (% predicted) 98 ± 3.6 47 ± 1 p < 0.001 50 ± 0.5
FVC post bronchodilator (% predicted) 96 ± 3.6 79 ± 1 p < 0.001 93 ± 0.9
HRCT measurements
Average % LAA≤ −950 HU 2.3 ± 1.6 15 ± 0.7 p < 0.001 N/A
% Emphysema <5% 85 31 N/A
% Emphysema 5- <10% 13 15 N/A
% Emphysema 10- <20% 2 25 N/A
% Emphysema ≥ 20% 0 29 N/A
Average % LAA≤ −910 HU 22.6 ± 3.7 39 ± 0.7 p < 0.001 40.7 ± 0.8
% Emphysema <35% 79 35
% Emphysema 35- <45% 15 19
% Emphysema 45- <55% 5 19
% Emphysema ≥55% 1 27
Average LP15A −916 ± 4.3 −944 ± 1.3 p < 0.001 −945 ± 1.3
Patient-reported outcomes
MRC dyspnea score 0.5 ± 0.1 2.2 ± 0.1 p < 0.001 2.0 ± 0.03
SGRQ 12 ± 3.9 39 ± 1.1 p < 0.001 46 ± 0.8
*Presented are the means ± standard errors for COPDGene cohort and TESRA cohort. p values represent difference between no COPD and COPD groups for
COPDGene. FEV1 = Forced expiratory volume at one second; FVC = forced vital capacity; LAA = low area attenuation; N/A = data not available; LP15A =mean lung
attenuation value at the 15th percentile on lung attenuation curve. MRC =Medical Research Council; SGRQ = St. George’s Respiratory Questionnaire.
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file 1: Table S2).
Biomarkers associated with emphysema
A full list of biomarkers analyzed in the COPDGene cohort
is available (Additional file 1: Table S3). After adjusting for
covariates, multiple regression analyses demonstrated a
total of 24 biomarkers associated with radiologic emphy-
sema including 15 biomarkers independently associated
with %LAA ≤ −950 HU (R2 = 0.4), 9 biomarkers associated
with %LAA ≤ −910 HU (R2 = 0.36) and 16 associated with
LP15A (R2 = 0.64, Table 2). There were 6 biomarkers that
were associated with all 3 radiologic emphysema outcome
variables. Advanced glycosylation end-product receptor
(RAGE) was negatively associated with more severe emphy-
sema (Figure 1A). In addition, intercellular adhesion mol-
ecule 1 (ICAM1, Figure 1B), macrophage inhibitory protein
3a (CCL20) and cadherin 1 (CDH1, Figure 1C) were nega-
tively associated with emphysema severity. Cadherin 13(CDH13, Figure 1D) and thyroxin-binding globulin (SER-
PINA7) were positively correlated with emphysema se-
verity (p < 0.001 for all comparisons). There were 3
biomarkers surfactant associated protein D (SFPD), FAS
ligand receptor (FAS), and malondialdehyde-modified
low-density lipoprotein (MDA LDL) associated with
both %LAA ≤ −910 HU and LP 15 emphysema out-
comes (Table 2).
Validation of emphysema biomarkers
Using similar statistical methods (modeling, covariates,
etc.), we attempted to validate the statistically significant
biomarkers using an independent cohort from the
TESRA study. Although %LAA ≤ −910 HU and LP15A
HRCT data were available in the TESRA cohort, %
LAA ≤ −950 HU measurements were not. Therefore, of
the total 16 biomarkers statistically associated with the
emphysema outcomes ≤ −910 and LP15A in the COPD-
Gene cohort, 9 biomarkers were available for validation
Table 2 Biomarkers and covariates associated with radiologic emphysema in the COPDGene cohort
(using multiple regression)*
%LAA≤ −950 HU %LAA≤ −910 HU LP15A#
Covariate Beta coefficient p-value Beta coefficient p-value Beta coefficient p-value
FEV1 (% predicted) −0.07 2.9 × 10
−40 −0.05 6.4 × 10−29 0.42 2.1 × 10−47
Body mass index −0.15 3.2 × 10−10 −0.26 8.2 × 10−22 1.37 3.4 × 10−21
Current active smoking −1.16 9.1 × 10−5 −0.76 1.3 × 10−7 4.56 7.5 × 10−7
Male gender 0.35 0.002 0.71 7.3 × 10−9 −9.57 0.0001
Age at enrollment 0.04 0.039 0.04 0.006 −0.20 0.039
Biomarker
RAGE −0.69 2.6 × 10−8 −1.10 0.005 10 0.0002
CCL20 (presence) −0.45 0.0006 −0.35 0.004 2.12 0.009
ICAM1 −0.42 0.001 −2.40 0.007 28.39 3.4 × 10−6
SERPINA7¶ 0.28 0.013 2.11 0.042 −13.69 0.038
CDH13¶ 0.29 0.025 2.62 0.005 −16.91 0.008
CDH1¶ −0.25 0.039 −2.04 0.006 13.09 0.006
TGFB1 LAP −0.54 0.0002
CCL13 0.35 0.013
TNFRSF11B 0.34 0.016
CCL8 −0.27 0.023
IgA −0.25 0.03 6.09 0.025
SORT1 −0.26 0.038
IL2RA 0.27 0.044
CCL2 0.25 0.045
IL12B (presence) 0.22 0.049
MDA LDL (absence)¶ 0.33 0.016 −2.07 0.025
FAS 1.16 0.016 −8.53 0.014
SFTPD −1.16 0.025 8.34 0.016
AXL 17.05 0.002
CXCL10 −11.80 0.002
ADIPOQ¶ −7.26 0.015
MB¶ −7.97 0.016
SOD1 11.08 0.009
NRCAM¶ −9.26 0.017
*Presented are beta coefficients and p values for multiple regression models of biomarkers and covariates associated with emphysema outcomes. %LAA = Percent
low attenuation areas; LP15A =mean lung attenuation at 15th percentile on lung attenuation curve; HU = Hounsfield units; FEV1 = Forced expiratory volume in 1
st
second; RAGE = Receptor for advanced glycosylation end products; CCL20 =Macrophage Inflammatory Protein-3 alpha; ICAM1 = Intercellular Adhesion Molecule 1;
SERPINA7 = Thyroxin-binding globulin; CDH 13 = Cadherin-13; CDH1 = Cadherin-1; TGFB1 LAP = Latency-Associated Peptide of Transforming Growth Factor beta 1;
CCL13 =Monocyte Chemotactic Protein 4; TNFRSF11B =Osteoprotegerin; CCL8 =Monocyte Chemotactic Protein 2; IgA = Immunoglobulin A; SORT1 = Sortilin; IL2RA=
Interleukin-2 receptor alpha; CCL2 =Monocyte Chemotactic Protein 1; IL-12B = Interleukin-12 Subunit p40; MDA LDL =Malondialdehyde-Modified Low-Density Lipoprotein;
FAS = FASLG Receptor; SFTPD= Surfactant protein D; AXL = AXL Receptor Tyrosine Kinase; CXCL10 = Interferon gamma Induced Protein 10; ADIPOQ=Adiponectin; MB =
Myoglobin; SOD1= Superoxide dismutase 1; NRCAM=Neuronal Cell Adhesion Molecule.
#Higher LP15A values indicate less severe emphysema, so positive coefficients are associated with less severe emphysema and negative coefficients are associated
with more severe emphysema unlike higher %LAA which is associated with more severe emphysema.
¶Biomarkers not available for replication in TESRA.
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for multiple testing, biomarkers RAGE (p = 1.2 × 10−9)
and ICAM1 (p = 1.5 × 10−7) were associated with %
LAA < −910 HU (Table 3). Similarly, with regard to the
LP15A emphysema outcome variable, meta-analysis
with the TESRA cohort validated the association ofRAGE (p = 2.5 × 10−10), ICAM1 (p = 6.0 × 10−11), and
AXL (p = 3.8 × 10−3) with radiologic emphysema inde-
pendent of covariates (Table 3). CCL20 was signifi-
cantly negatively associated with emphysema in both
the TESRA and COPDGene cohorts; however, meta-
analysis was not possible due to CCL20 being binary in
Figure 1 Biomarkers associated with CT-assessed emphysema in the COPDGene cohort. (A) Advanced glycosylation end-product receptor
(RAGE); (B) Intracellular adhesion molecule 1 (ICAM1); (C) Cadherin 1 (CDH1); (D) Cadherin 13 (CDH13). *Presented are normal quantile transformed
biomarker levels on the ordinate and percent emphysema (% low attenuation≤−950 HU) on CT scan on abscissa (p < 0.001 for all comparisons).
Table 3 Meta-analysis of biomarkers associated with emphysema in COPDGene and TESRA cohorts*
COPDGene TESRA Adjusted
meta-analysis
p-value
Variable Beta coefficient p-value° Beta coefficient p-value°
Percent LAA≤ −910 HU
RAGE −1.4 2.6 × 10−5 −0.52 9.2 × 10−7 1.2 × 10 −9
ICAM1 −3.2 9.2 × 10−6 −0.37 3.4 × 10−4 1.5 × 10−7
CCL20# −0.87 1.3 × 10−4 −0.29 2.2 × 10−3 N/A
Mean lung attenuation at 15th percentile
RAGE 10.78 1.3 × 10−5 7.08 3.0 × 10−8 2.5 × 10 −10
ICAM1 32.3 1.1 × 10−9 5.14 4.5 × 10−5 6.0 × 10−11
AXL 18.8 1.8 × 10−4 2.53 0.038 3.8 × 10−3
CCL20# 6.44 8.2 × 10−5 4.45 1.3 × 10−4 N/A
*Presented is the regression analysis for each biomarker with an adjusted meta-analysis p value. LAA = low attenuation area; RAGE = Receptor for advanced
glycosylation end products; ICAM1 = Intercellular Adhesion Molecule 1; CCL20 =Macrophage Inflammatory Protein-3 alpha; AXL = AXL Receptor Tyrosine Kinase;
°p values for COPDGene and TESRA are two-sided p values.
#CCL20 was a binary variable in COPDGene, therefore it is the presence CCL20 that is negatively associated with emphysema in COPDGene cohort, while CCL20 was a
continuous variable in TESRA also associated negatively associated with more severe emphysema. Meta-analysis was not possible given difference in variables (N/A).
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significant in the COPDGene study such as CDH1,
CDH13, SERPINA7, MDA LDL, MB, NRCAM, and
ADIPOQ were not measured in the TESRA study and
therefore could not be included in the meta-analysis.
ROC curves for covariates age, gender, BMI, current
smoking status and FEV1 had an area under the curve
(AUC) of 0.88 for the prediction of emphysema. ROC
curves demonstrated a slight improvement in the AUC
after adding 15 biomarkers to the model, raising the
AUC to 0.92 (Additional file 1: Table S4 and Figure S1).
However, when only considering those without severe
airflow limitation (FEV1 ≥ 50%, n = 399), the AUC was
0.78 using covariates alone and the AUC increased to
0.85 when the biomarker panel was added to the model.
Discussion
COPD is a phenotypically heterogeneous disease, with the
presence of emphysema having implications for risk stratifi-
cation and management [3-5,18]. In this study, we success-
fully identified and replicated a panel of peripheral blood
biomarkers that was associated with emphysema independ-
ent of age, smoking status, body mass index, airflow limita-
tion, and gender. These biomarkers (AGER, ICAM1 and
CCL20) were associated with emphysema regardless of
quantification technique (%LAA ≤ −950 and ≤ −910 HU
and LP15A) and were replicated in an independent
COPD cohort (TESRA), thus strengthening their poten-
tial utility for defining clinically relevant emphysema.
Our study reports lower RAGE levels in peripheral
blood as a biomarker of increased emphysema percent-
age in the lungs independent of gender, age, airflow limi-
tation, body mass index and current smoking status.
RAGE (advanced glycosylation end-product receptor or
AGER) is an immunoglobulin family member that is
highly expressed in human lung [25]. The RAGE path-
way and soluble RAGE (sRAGE), a splice variant or pro-
teolytic cleavage product of RAGE, have been associated
with several inflammatory conditions such as diabetes
mellitus, vascular disease and arthritis [26,27]. The sRAGE
molecule binds damaged ligands preventing these from
binding to cell surface receptors and activating cell signal-
ing pathways [28]. RAGE is active in damage-related con-
ditions such as hyperglycemia, hypoxia, inflammation and
oxidative stress [29]. While fasting blood glucose measure-
ments were not available, 66 individuals reported a history
of diabetes mellitus in the COPDGene biomarker study
and there was no association between RAGE levels and
self-reported history of diabetes mellitus (p = 0.88). Lower
levels of sRAGE have been described in individuals with
airflow limitation [30,31]. Other studies have found lower
sRAGE levels associated with CT-assessed emphysema se-
verity and cor pulmonale [32] and with CT-assessed em-
physema and lower diffusing capacity of carbon monoxideusing the TESRA data described in this study in combin-
ation with the ECLIPSE investigators [13]. Some studies
suggest that sRAGE is increased in the lungs of patients
with COPD and high levels of sRAGE may be associated
with progression of emphysema [33]. Interestingly, animal
studies suggest RAGE/sRAGE plays a role in alveolar de-
velopment and overexpression in mouse lung leads to
the development of emphysema [34]. This suggests that
sRAGE, by acting as a decoy molecule, may have a differ-
ent role in the developing lung and the adult lung or low
sRAGE levels in COPD may result in increased inflamma-
tory signaling in the lung.
In the present study, we found decreased ICAM1
levels correlate with increased severity of emphysema on
CT scan, independent of smoking status, FEV1 and other
covariates. ICAM1 is expressed on vascular endothelial
and immune cells and mediates cell transmigration and
adhesion [35]. ICAM1 plays a role in the recruitment of
inflammatory cells to the lung. There is currently quite
limited information about the association of ICAM1 to
COPD and emphysema. Higher serum levels of soluble
ICAM1 have been demonstrated in COPD, where it cor-
related with the severity of airflow limitation, arterial
hypoxemia and hypercarbia [36,37]. Other studies relate
ICAM1 levels to active smoking [38] and preliminary
analysis from The MESA Lung Study demonstrated that
ICAM1 predicted 0.15%/year increase in CT-assessed
emphysema, suggesting a role for this molecule as a bio-
marker of emphysema and that it may play a role in em-
physema pathogenesis [39].
CCL20 or macrophage inhibitory protein 3a, a chemo-
kine receptor ligand, is involved in the recruitment of in-
flammatory cells through chemokine receptor 6 (CCR6),
its only known receptor [40]. In both the COPDGene
study and the TESRA study, CCL20 levels were inversely
and significantly associated with emphysema although
methodological considerations prevented a meta-analysis.
Lower CCL20 levels have been described in bronchoalveo-
lar lavage fluid of smokers [41]. The CCR6/CCL20 com-
plex is one of the most potent regulators of dendritic cell
migration to the lung and CCR6 knockout mice may be
partially protected against cigarette smoke-induced em-
physema due to reduced recruitment of inflammatory cells
to the lung [42]. These data suggest that increased activity
of the CCL20/CCR6 pathway may increase the susceptibil-
ity to emphysema.
CDH1 was negatively correlated with radiologic emphy-
sema across all emphysema outcome measurements.
CDH1 or E cadherin is an epithelial cell adhesion molecule
that regulates cell differentiation and morphogenesis, and is
associated with lung fibrosis and cancer [43]. CDH1 may
be a marker of epithelial cell injury and epithelial to mesen-
chymal transition that is believed to play a role in small air-
way remodeling in COPD [44]. Genetic polymorphisms in
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and decline in lung function [45]. CDH13 or H cadherin is
another adhesion molecule that may influence surfactant
protein D levels and serum adiponectin levels, both impli-
cated in the pathogenesis of COPD; however, CDH13 itself
has not been associated with quantitative emphysema to
date [46,47]. We found higher levels of CDH13 to be asso-
ciated with CT-assessed emphysema in the COPDGene
cohort, but these were not available for validation in the
TESRA cohort. Higher SERPINA7 levels were also associ-
ated with more radiologic emphysema. SERPINA7 does
not have protease inhibitor capabilities and is also known
as thyroid binding globulin. This study represents a new
association for SERPINA7 with COPD.
With regard to the ability of biomarkers to predict the
presence of any emphysema compared to no emphysema,
ROC curves demonstrated a small contribution of plasma
biomarkers separate to the covariates alone. This is likely
because when individuals with more severe levels of em-
physema are included, covariates alone, especially FEV1, are
highly predictive of emphysema in their own right. How-
ever, the biomarkers are more useful for predicting the
presence of emphysema in those that do not already have
severe airflow limitation, because the covariates alone were
not as good at predicting emphysema in this group and
biomarkers combined with covariates increased the area
under the curve. This may be useful clinically since deter-
mining the presence of underlying emphysema at this early
stage in those that do not yet have severe airflow limitation
may have outcome benefits for the individuals [3-6].
This COPDGene biomarker study is one of the largest
emphysema biomarker studies to date on carefully pheno-
typed individuals with COPD. The TESRA cohort pro-
vides validation of a number of the findings. The study
confirms a previously identified association between radio-
logic emphysema and sRAGE, builds on data suggesting a
role for ICAM1 as a biomarker, in addition to discovering
previously not identified biomarkers associated with em-
physema such as CCL20, cadherin 1, cadherin 13 and
SERPINA7. The study also highlights the potential useful-
ness of a panel of biomarkers to predict the presence of
emphysema compared to using clinical data alone, espe-
cially in those who do not yet have severe abnormalities in
lung function. However there are limitations; the TESRA
cohort was different from the COPDGene cohort in that
its population was comprised of ex-smokers with at least
mild COPD and did not include control subjects and only
2 of the 3 quantitative emphysema measurements were
made (−910 HU and LP15A). Since emphysema can occur
in smokers without COPD and emphysema measurements
are highly co-linear, these limitations may be of minor im-
portance. Other limitations include the fact that the ma-
jority of subjects in both cohorts were non-Hispanic
white, thus, the generalizability of these findings to otherpopulations remains unknown and emphysema measure-
ments from both COPDGene and TESRA were cross sec-
tional; therefore, the significance of these biomarkers for
emphysema progression remains unknown. A final limita-
tion of this study, an in many biomarker studies, is the
magnitude of association between the change in biomarker
levels and the change in emphysema severity. While the
biomarker associations are highly statistically significant,
and validation suggests the associations are real, further
studies are needed to evaluate the role of these biomarkers
in disease pathogenesis and as markers of disease presence
and progression [48,49].
Conclusion
Our findings, particularly when combined with other
studies of individual biomarkers, suggest that a panel of
blood biomarkers including sRAGE, ICAM1 and CCL20
may serve as a useful surrogate measure of emphysema
and may shed light on disease pathogenesis, providing
targets for new treatments. Other biomarkers such as
CHD1, CDH13 and SERPINA7 may also have a role in
evaluating emphysema (especially milder emphysema), al-
though require confirmation in other cohorts. Overall,
these peripheral blood biomarkers could ultimately be
used to diagnose emphysema at subclinical stages thereby
reducing the need for CT, and perhaps may provide in-
sights into disease prediction and progression.Additional file
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